NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson’s Disease Patients with Motor Fluctuations

• ND0612, a continuous 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint (“ON” time without troublesome dyskinesia, also called “Good ON” time) and the key secondary endpoint (“OFF” time).¹
• ND0612 also demonstrated superior efficacy on several pre-defined secondary endpoints, including the MDS-Unified Parkinson's Disease Rating Scale Part II score (MDS-UPDRS motor experiences of daily living sub-score), Patient Global Impression of Change (PGIC) and Clinical Global Impression of Improvement (CGI-I).¹
• ND0612 systemic adverse events were typical to the well-established safety profile of oral LD/CD. ^1,3 Infusion site reactions associated with ND0612 treatment were mostly non-serious and mild to moderate in severity.¹
• ND0612 was well tolerated, with only 6.3% of patients randomized to ND0612 discontinuing the trial, including 5.5% who discontinued due to adverse events.¹

– NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced highly positive results from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial. The trial, which evaluated ND0612 – a continuous, 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for Parkinson’s Disease (PD) patients with motor fluctuations – met its primary endpoint of “Good ON” time.¹  

Following two sequential open-label periods to optimize oral LD/CD and ND0612, patients were randomized to either ND0612 or oral LD/CD for a 12-week DBDD period.⁴ Treatment with ND0612 demonstrated superiority over oral LD/CD, with a statistically significant difference (p<0.0001) of 1.72 hours in “Good ON” time.

The trial also demonstrated positive and clinically meaningful results for the key secondary endpoint of “OFF” time (p<0.0001) and other secondary endpoints including the MDS-Unified Parkinson's Disease Rating Scale Part II score (MDS-UPDRS motor experiences of daily living sub-score) (p<0.0001); the Patient Global Impression of Change (PGIC) (p<0.0001); and the Clinical Global Impression of Improvement (CGI-I) (p<0.0001).¹  

“With these positive results for the primary endpoint and four secondary endpoints, ND0612 has confirmed its potential as an effective treatment strategy for Parkinson’s disease patients with motor fluctuations, despite optimization of oral therapies,” said Professor Alberto Espay, MD, FAAN, Primary U.S. Investigator of BouNDless and Director of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the University of Cincinnati. “Continuous subcutaneous LD/CD treatment shows promise to change the treatment paradigm and transform the lives of patients with Parkinson’s disease.”

The systemic safety profile of ND0612 was consistent with the well-established safety profile of oral standard of care LD/CD.¹ Out of the most common (≥5%) adverse events (AEs) reported in any treatment group during the DBDD period, some infusion site reactions (hematoma, infection and erythema) were more frequently reported in the ND0612 group compared to oral LD/CD, while “on and off phenomenon” and falls were less frequently reported in the ND0612 group compared to oral LD/CD. 

Only 6.3% of patients randomized to ND0612 discontinued the trial during the DBDD period due to any reason – including 5.5% due to AEs, compared to 6.1% and 3.1%, respectively, of patients randomized to oral LD/CD.¹

“These results are meaningful to both patients and healthcare providers, as there will be a novel, minimally invasive, continuous subcutaneous LD/CD treatment option demonstrating encouraging efficacy and tolerability, thereby helping patients stay on treatment with better motor function – an important milestone leading to better health outcomes and less clinical burden for people with PD experiencing motor fluctuations,” said Professor Olivier Rascol, Primary Investigator of BouNDless in Europe and Israel, Professor of Clinical Pharmacology at Toulouse University Hospital and chair of the French NS-Park clinical research network on Parkinson’s disease.

“We are extremely encouraged by the positive outcome of the Phase III BouNDless trial. People with Parkinson’s disease experiencing motor fluctuations have limited options to manage their condition. These remarkable results confirm the potential of ND0612 as an effective and well-tolerated treatment option to better control motor fluctuations – addressing a significant, unmet need,” said Tami Yardeni, EVP, Clinical Development, NeuroDerm. “We are thankful to everyone who participated in this important trial and remain committed to improving the quality of life for people with Parkinson’s disease and their families.” 

Analyses of results from the ongoing BouNDless trial complement the long-term safety data assessing ND0612 with up to 7 years of follow-up.⁵ Additional data will be presented at upcoming medical meetings; submissions to regulatory authorities are anticipated in the United States this year and later in the European Union.